Cyston Tablet: Indication and Dose
Based on the available evidence, Cyston is not a recognized pharmaceutical agent in established medical guidelines or FDA-approved drug databases for urinary tract infections. The provided evidence contains no information about "Cyston" as a treatment option for UTIs or any other urological condition.
What the Evidence Shows
The comprehensive guidelines and research provided focus exclusively on established antimicrobial agents and evidence-based treatments for urinary tract infections, including:
For Uncomplicated Cystitis (First-Line Options):
- Fosfomycin trometamol 3g single dose for 1 day 1
- Nitrofurantoin 50-100mg four times daily for 5 days 1
- Pivmecillinam 400mg three times daily for 3-5 days 1
Alternative Agents When Resistance Patterns Allow:
- Trimethoprim-sulfamethoxazole 160/800mg twice daily for 3 days (only if local E. coli resistance <20%) 1
- Cephalosporins (e.g., cefadroxil) 500mg twice daily for 3 days 1
For Complicated or Resistant Infections:
- Ceftazidime-avibactam 2.5g IV every 8 hours for carbapenem-resistant Enterobacterales 1
- Meropenem-vaborbactam 4g IV every 8 hours for complicated UTIs due to CRE 1
Important Clinical Caveat
If "Cyston" refers to a herbal or complementary medicine product, it would fall outside evidence-based guideline recommendations for treating active urinary tract infections. While some non-antibiotic treatments have been studied for UTI prevention (cranberry products, D-mannose, probiotics), these have weak and contradictory evidence and are not recommended as primary treatment for active infections 1, 2.
For symptomatic relief only in mild uncomplicated cystitis, ibuprofen may be considered as an alternative to antimicrobial treatment in consultation with patients 1, but this does not treat the underlying infection and carries risk of progression.
Recommendation for Clinical Practice
Use guideline-recommended antimicrobial agents listed above based on local resistance patterns and patient factors 1. If a patient inquires about "Cyston" or similar herbal products, counsel them that these lack robust evidence for treating active UTIs and may delay appropriate antimicrobial therapy, potentially leading to complications including pyelonephritis and renal scarring.